Senior Director, Payor and Health Systems Liaison, West

Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: Reporting to the Executive Director of Field Medical Affairs, the Payor and Health Systems Liaison will own and shape the scientific payer/access strategy for the US region. They will develop and cultivate relationships with key decision-makers and other influencers in managed care organizations, government programs, employers, hospital systems and product distribution companies, to support appropriate patient access and evidence-based utilization for Revolution Medicine’s products. A key aspect of the Payor and Health Systems Liaison responsibilities is to keep payers and other key external constituents or influencers abreast of new product launches, line extensions and Medical Affairs research. The Payor and Health Systems Liaison leads high‑impact clinical, scientific, and population health engagement with external access stakeholders, including Payers, Group Purchasing Organizations (GPOs), Community Aggregators, and Integrated Delivery Networks (IDNs), while ensuring strong integration between Medical Affairs, HEOR, and Market Access strategy. Responsibilities will include: Collaborates with Field Medical Executive Director, MSL Regional Sr. Directors, and US Strategy leads to define the US clinical value strategy and population health scientific messaging for both marketed and pipeline assets, from pre‑approval through lifecycle management. Partners closely with Market Access, HEOR, and Evidence Generation leaders to align payer value strategy, evidence planning, and field execution. Leads high‑level scientific and clinical value discussions with commercial and government payers, GPOs, IDNs, community and regional aggregators, and other risk‑bearing entities. Engages access stakeholders in credible, non‑promotional dialogue on clinical outcomes, real‑world evidence, and unmet medical needs aligned with approved scientific exchange frameworks. Support pathway, guideline, and formulary‑relevant engagement by providing medical insight into clinical evidence, value narratives, and population‑level considerations. Participates in executive‑level payer forums, advisory boards, and access‑focused conferences as a senior medical representative of the company. Serves as a senior Medical Affairs voice for managed care insights across internal stakeholders, including Medical, Market Access, and cross‑functional leadership. Synthesizes and communicates actionable insights on: Access barriers and opportunities Payer evidence expectations Population‑level treatment trends Contributes to medical strategy, launch readiness, and lifecycle planning from a managed care and access perspective. Identifies opportunities to support compliant and effective cross-functional collaboration across Medical Affairs and Commercial teams, as needed and appropriate. Exhibits significant leadership experience in the pharmaceutical and managed care industries with the ability to work independently and collaboratively in cross functional team environment. Required Skills, Experience and Education: Advanced, medical/scientific doctoral level degree required: MD, PharmD, PhD. 10-13+ years of progressive experience in pharmaceutical/biotechnology Medical Affairs, managed care, market access–adjace